emba

What the maker publishes

Biomarker discovery

It groups models by predictive performance or synergy prediction and compares average network node activity across model groups to identify biomarkers. source

Biomarker types

The package supports synergy biomarkers, performance biomarkers, and link operator biomarkers for qualifying Boolean models. source

DrugLogics data

The package loads simulation results from DrugLogics, a pipeline used to predict synergistic drug combinations in cancer cell lines. source

Input requirement

Gold-standard drug combinations must be a subset of the combinations tested in the model predictions. source

Inputs

The documented analysis uses model predictions, model stable states, observed gold-standard synergies, and optionally model link operators. source

Install

The project page lists installation from CRAN and a development version installable from GitHub with remotes. source

Intended users

The package is intended for analysis of Boolean model ensembles, including research into drug synergy and biomarkers in cancer cell networks. source

License

The project page identifies the license as MIT. source

Performance metrics

Models can be grouped by true positive prediction counts or Matthews correlation coefficient scores. source

Purpose

emba is an R package for analyzing and visualizing biomarkers in ensembles of Boolean models for cancer cell networks. source

Support

The project directs users to GitHub Issues to report bugs. source

Visualization

The guide demonstrates plotting average activity differences and link operator differences on a network graph. source

Checked against the maker's pages on 5 Oct 2026.